louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02002481: Comparison of the Quality of CPR by Professional Helpers (Emergency Physicians / Paramedics) During Flights
Official title: Vergleich Der Qualität Der Kardiopulmonalen Reanimation Durch Professioneller Helfer (Notärzte / Rettungsassistenten) während Lufttransporten
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiac Arrest
Lead sponsor: University Hospital of Cologne
Sponsor class: OTHER
First posted: 2013-12-05
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Investigation of the influence of narrowness and unusual circumstances on the CPR-quality

Detailed description: Even for paramedics and emergency physicians, the resuscitation of patients with cardiac arrest remains a challenge. Previous studies have shown that the cardiac output varies widely even under normal ambient conditions. Especially the mean frequenices of cardiac compression varies from 60 to 160/min, as well as the now-flow-time. Aim of this study is to investigate how narrowness and movement during a transport affect the CPR-performance.

For this, we examine the impact of the common transport options (air and ground) on the outcome-varity on a manikin. The subjects for this study are professional rescuers (emergency physicians / paramedics) who perform a 10 minute ALS-CPR in either normal circumstances (resuscitation-room) or during transportation.

Eligibility criteria: Inclusion Criteria:

* emergency physician
* paramedic
* \> 18 years
* \< 60 years

Exclusion Criteria:

* pregnant
* lay rescuers

Primary outcomes:
measure: The average achieved cardiac output
timeFrame: after 10 minutes
Secondary outcomes:
measure: Now-flow-time
timeFrame: after 10 minutes
Other outcomes:
Locations:
city: Köln
country: Germany
facility: Uniklinik Köln
state: NRW
Study officials:
affiliation: University Hospital Cologne
name: Stefan Braunecker, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Cologne
name: Jochen Hinkelbein, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University Hospital Cologne
name: Jan Hilgers, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01608581: Development and Evaluation of an Adult Burn Prevention Program
Official title: Development and Evaluation of an Adult Burn Prevention Program
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Burns
Keywords: prevention
burn
adult
health promotion
evaluation
media
Lead sponsor: The University of Queensland
Sponsor class: OTHER
First posted: 2012-05-31
Enrollment: 1637
Sex: MALE
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim of this study was to evaluate the effectiveness of a targeted burn prevention message on burn safety knowledge and behavior.

Detailed description: Flammable liquid burns comprise 23% of admissions to our burn center. This was a project to test the uptake of the message "Don't be a Flaming Fool" delivered via multi-media campaign.

Eligibility criteria: Inclusion Criteria:

* male 16 years of age or older

Exclusion criteria

* males less than 16 years of age
* females

Primary outcomes:
measure: Changes in burn safety knowledge at 3 months
timeFrame: Pre intervention, 3 months post intervention
measure: Changes in burn safety knowledge at 12 months
timeFrame: pre-intervention and 12 months post-interevention
Secondary outcomes:
Other outcomes:
Locations:
city: Brisbane
country: Australia
facility: Royal Brisbane and Women's Hospital
state: Queensland
Study officials:
affiliation: The University of Queensland
name: Michael J Muller, FRACS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05818995: Therapeutic Drug Use for CKD Patients
Official title: Therapeutic Drug Use in Patients With Chronic Kidney Disease (CKD): a Multicenter Retrospective Real-world Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chronic Kidney Disease
Keywords: Chronic kidney disease
Diabetes nephropathy
Drug effectiveness
Drug safety
Drug economics
Lead sponsor: Qianfoshan Hospital
Sponsor class: OTHER
First posted: 2023-04-19
Enrollment: 10000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients diagnosed with chronic kidney disease from July 1, 2020 to June 30, 2022

Brief summary: Chronic kidney disease (CKD), characterized as renal dysfunction, is recognized as a major public health problem with high morbidity and mortality worldwide. This study aimed to analyze the common drug use and combinations of different stages and types of CKD patients. The study is a multicenter retrospective study involving three hospitals. Investigators reviewed and analyzed all patients diagnosed with chronic kidney disease from July 1, 2020 to June 30, 2022. Chronic kidney disease was defined as eGFR less than 60 mL/min per 1·73 m(2) or the presence of albuminuria. The study selected seven types of drugs based on hospital electronic medical record data, including β Receptor blockers, angiotensin converting enzyme inhibitor blockers, angiotensin II receptors, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and calcium channel blockers. Chi-square test, Mann-Whitney Wilcoxon test, and Kruskal Wallis test will be used for statistical analysis. The main purpose of this study is to provide evidence for promoting rational drug use in CKD patients by describing the drug use. The secondary purpose of the study is to explore the efficacy, safety and economy of SGLT-2 inhibitors in diabetes nephropathy (DN).


Eligibility criteria: Inclusion Criteria:

1. Visit time (based on admission time for inpatients) is from July 1, 2020 to June 30, 2022
2. Any diagnostic type of the patient's visit includes CKD related diagnostics
3. Age ≥ 18 years old

Exclusion Criteria:

1. Diagnosis includes malignant tumors
2. Diagnosis includes uremia, hemodialysis, or peritoneal dialysis
3. Diagnosis includes jaundice
4. Incomplete clinical data

Primary outcomes:
measure: eGFR
timeFrame: October , 2023
measure: albuminuria
timeFrame: October , 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Xiao Li，MD
state: Shandong
Study officials:
References:
Clinical trial NCT04812795: Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches
Official title: Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cigarette Smoking Behavior
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
name: Michigan State University
name: Harvard School of Public Health (HSPH)
name: Stanford University
name: Dana-Farber Cancer Institute
name: Fenway Community Health
First posted: 2021-03-24
Enrollment: 2214
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants will be randomly assigned to the tailored or non-tailored arms using random assignment function within survey software.
Primary purpose: OTHER

Brief summary: Project RESIST is an R01 study funded by NCI focused on determining the effects of using culturally tailored inoculation approaches to increase resilience to tobacco marketing influences among young adult sexual minority women ages 18-30 and incorporates critical stakeholder inputs that support later adoption and implementation. The study team is utilizing formative research to design and pre-test anti-smoking messages and two national longitudinal online survey experiments.

Detailed description: This study will recruit 2000 young adult sexual minority women (SMW), ages 18-30 years, current smokers (n = 1000) and not current smokers (n=1000). The study team will randomly assign participants to a condition in which they will be exposed to either culturally tailored anti-smoking messages or non-tailored. Participants will receive these messages at baseline and 1, 2, and 3 weeks post baseline. They will be asked to complete a follow-up survey one month post baseline. Intentions to quit smoking as well as intention (among current smokers) and intention to purchase cigarettes (among current nonsmokers) will be measured at baseline and one-month post baseline.

Eligibility criteria: Inclusion Criteria:

* Ages 18-30
* Woman
* Identifies as a sexual minority (any sexual orientation other than heterosexual)
* Lives in the United States
* Able to take surveys in English

Exclusion Criteria:

* Under 18 or older than 30
* Men
* Heterosexual
* Lives outside the United States
* Unable to take survey in English

Primary outcomes:
measure: Intention to Quit Smoking
timeFrame: Day 30
measure: Change in Intention to Purchase Cigarettes
timeFrame: Day 30
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University
state: California
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
References:
Clinical trial NCT00660595: Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
Official title: A Pilot Study of Three-Week, Randomised, Open Comparison in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Schizophrenic Disorders
Keywords: Schizophrenia
Schizoaffective psychosis
Schizophreniformic psychosis
Pilot study
Quetiapine Prolong
Risperidone
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-04-17
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and Statistical Manual (DSM - IV) with the first visits on days 1, 2, 4 or 5 and 7 ± 1.


Eligibility criteria: Inclusion Criteria:

* In the opinion of the Investigator, requirement for treatment for an acute episode of schizophrenia, schizoaffective disorder or schizophreniformic psychosis (according to DSM-IV diagnostic criteria), Positive and Negative Symptoms Scale (PANSS) ≥ 65, CGI ≥ 4

Exclusion Criteria:

* Pregnancy or lactation
* In-patients/hospitalized \> 7 days before enrollment
* Known intolerance or lack of response to quetiapine fumarate or risperidone, as judged by the investigator

Primary outcomes:
measure: Change From Baseline in Positive and Negative Symptoms Scale, Excitatory Subscale (PANSS-EC) Score (Time Frame: 3 Weeks)
timeFrame: baseline and 3 weeks
Secondary outcomes:
measure: Change From Baseline in Clinical Global Impression, Severity Scale (CGI-S) and in Absolute Clinical Global Impression, Improvement Scale (CGI-I) (Performed 4 Times/ 3 Weeks)
timeFrame: baseline and 3 weeks
measure: Change From Baseline in Overt Aggression Scale (OAS) (Performed 6 Times/ 3 Weeks)
timeFrame: baseline and 3 weeks
measure: Change From Baseline in Total Positive and Negative Symptoms Scale (PANSS Score) (Performed 5 Times/ 3 Weeks)
timeFrame: baseline and 3 weeks
Other outcomes:
Locations:
city: Harjavalta
country: Finland
facility: Research Site
city: Helsinki
country: Finland
facility: Research Site
city: Pitkaniemi
country: Finland
facility: Research Site
city: Turku
country: Finland
facility: Research Site
Study officials:
affiliation: AstraZeneca Finland
name: Yrjö Ovaskainen, MD
role: STUDY_DIRECTOR
affiliation: Kuopio University
name: Hannu Koponen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02917395: Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients
Official title: Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients; Comparison of Two Echocardiography Based Methods: Global Longitudinal Strain vs. Left Ventricle Ejection Fraction
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiomyopathy
Keywords: hypertrophic cardiomyopathy, disopyramide,
Lead sponsor: Rabin Medical Center
Sponsor class: OTHER
First posted: 2016-09-28
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Population study- patients with obstructive hypertrophic cardiomyopathy that are treated with disopyramide.

Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.

Detailed description: Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.

Eligibility criteria: Inclusion Criteria:

* hypertrophic cardiomyopathy that treated with disopyramid

Exclusion Criteria:

* pregnancy
* pacemaker

Primary outcomes:
measure: Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide
timeFrame: 2-3 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Rabin Medical Center
name: Idit Yedidya, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00800995: Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
Official title: SOD as Antioxidant Treatment OF ARMD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Age Related Macular Degeneration
Keywords: ARMD
SOD
Lead sponsor: Centre de Recherche en Nutrition Humaine Rhone-Alpe
Sponsor class: OTHER
First posted: 2008-12-03
Enrollment: 46
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: INTRODUCTION:

Acting directly on the anti-radical enzyme chain, the superoxide dismutase (SOD), a major enzyme of the anti-oxidant system, provides an alternative of the antioxidants treatment in ARMD. Its synthesis depends on the cellular oxygenated reactive species, and leads to the conversion of the superoxide ion (O2-) into hydrogen peroxide (H2O2). This compound is the cell watch guard continuously regulating a free radicals' detoxifying chain. Subsequently, by increasing the production of H2O2, the administration of SOD can trigger endogenous/internal antioxidant mechanisms.

Oral administration of SOD is possible in its galenic form, Glisodine. The purpose of this study was to evaluate the protective effect of SOD on the bilateralization of the disease.


Eligibility criteria: Inclusion Criteria:

* unilateral neo-vascular ARMD

Exclusion Criteria:

* other pathology

Primary outcomes:
measure: difference on AREDS score, Month 24 - Month 0
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Grenoble
country: France
facility: Centre Hospitalier Universitaire de Grenoble
Study officials:
References:
Clinical trial NCT00787995: A Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
Official title: A Multicenter, Multinational, Longitudinal Clinical Assessment Study of Subjects With Mucopolysaccharidosis IVA (Morquio Syndrome)
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: MPS IV A
Mucopolysaccharidosis IVA
Morquio A Syndrome
Keywords: Mucopolysaccharidosis IV type A
MPS IV Type A
Mucopolysaccharidosis IVA
MPS IVA
Morquio A Syndrome
Lysosomal Storage Disorder
LSD
N-acetylgalactosamine-6-sulfatase
galactose-6-sulfatase
GALNS
enzyme replacement therapy
ERT
Lead sponsor: BioMarin Pharmaceutical
Sponsor class: INDUSTRY
First posted: 2008-11-10
Enrollment: 353
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects diagnosed with MPS IVA

Brief summary: This multicenter, multinational, longitudinal study will quantify endurance and respiratory function in subjects diagnosed with MPS IVA and will better characterize the spectrum of symptoms and biochemical abnormalities in MPS IVA disease over time.


Eligibility criteria: Inclusion Criteria:

* Willing and able to provide written, signed informed consent, or in the case of subjects age \< 18 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.
* Documented history of reduced GALNS activity relative to the normal range of the laboratory performing the assay, or documented result of molecular genetic testing confirming diagnosis of MPS IVA.
* Willing and able to comply with all study procedures.

Exclusion Criteria:

* Use of any investigational product or investigational medical device within 30 days prior to screening.
* Previous hematopoietic stem cell transplant (HSCT).
* Concurrent disease or condition that would interfere with study participation or pose a safety concern.

Primary outcomes:
measure: Endurance
timeFrame: Study Visit
measure: Respiratory Function
timeFrame: Study Visit
Secondary outcomes:
Other outcomes:
Locations:
city: Oakland
country: United States
state: California
city: Chicago
country: United States
state: Illinois
city: Cordoba
country: Argentina
city: Porto Alegre
country: Brazil
city: Sao Paulo
country: Brazil
city: Montreal
country: Canada
state: Quebec
city: Lyon
country: France
city: Paris
country: France
city: Mainz
country: Germany
city: Monza
country: Italy
city: Amsterdam
country: Netherlands
city: Taipei
country: Taiwan
city: Birmingham
country: United Kingdom
city: London
country: United Kingdom
city: Manchester
country: United Kingdom
Study officials:
affiliation: BioMarin Pharmaceutical
name: Celeste Decker, MD
role: STUDY_DIRECTOR
References:
citation: Martell LA, Cunico RL, Ohh J, Fulkerson W, Furneaux R, Foehr ED. Validation of an LC-MS/MS assay for detecting relevant disaccharides from keratan sulfate as a biomarker for Morquio A syndrome. Bioanalysis. 2011 Aug;3(16):1855-66. doi: 10.4155/bio.11.172.
Clinical trial NCT01554995: A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study
Official title: A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCB01-0371 in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: LCB01-0371
Lead sponsor: LigaChem Biosciences, Inc.
Sponsor class: INDUSTRY
First posted: 2012-03-15
Enrollment: 70
Sex: MALE
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Primary

- To investigate the safety and tolerability of LCB01-0371 after a single oral dose

Secondary

* To investigate the pharmacokinetic characteristics of LCB01-0371 after a single oral dose
* To investigate the safety of LCB01-0371 after a single oral dose

Detailed description: * To investigate the pharmacokinetic characteristics of LCB01-0371 after a single oral dose
* To investigate the safety of LCB01-0371 after a single oral dose

Eligibility criteria: Inclusion Criteria:

1. Healthy Male between 20 and 45 years of age at the time of screening
2. Subjects with body mass index (BMI) between 20 and 27 at the time of screening
3. Agree to continue to use a medically reliable dual contraception and not to donate sperm until 30th days of study completion
4. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements

Exclusion Criteria:

1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic, neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).
2. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer) which is affect to absorption within 6 months from screening
3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the LCB01-0371, same class of the study drugs (linezolid), or other drugs including aspirin and antibiotics.
4. History of drug abuse or positive result at urine drug screening test
5. AST, ALT, r-GT, billirubin(total) values over than 1.5 times of ULN

Primary outcomes:
measure: safety and tolerability
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul,
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Asan Medical Center
name: Kyun-Seop Bae, M.D., Ph. D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cho YS, Lim HS, Lee SH, Cho YL, Nam HS, Bae KS. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single-Dose Oral LCB01-0371, a Novel Oxazolidinone with Broad-Spectrum Activity, in Healthy Volunteers. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e00451-18. doi: 10.1128/AAC.00451-18. Print 2018 Jul.
Clinical trial NCT01452295: Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
Official title: Registry Protocol for Tracking the Incidence of Transplant, the Incidence and Type of Cancer, and Survival Rate of Subjects Participating in Protocol VTI-206 (NCT00973817)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Acute Liver Failure
Keywords: liver
liver failure
acute liver failure
ELAD
alcoholic hepatitis
acute on chronic hepatitis
Lead sponsor: Vital Therapies, Inc.
Sponsor class: INDUSTRY
First posted: 2011-10-14
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: VTI-207 (NCT01452295) is designed to follow subjects, both treated and control, for five years after their completion of study participation in protocol VTI-206 (NCT00973817) to gather information relating to the incidence of liver transplant, the incidence and type of cancer (if any), and survival.

Detailed description: Vital Therapies, Inc. (VTI) is conducting clinical trial VTI-206 in which subjects with acute on chronic hepatitis (AOCH) and acute alcoholic hepatitis (AAH) are treated with the ELAD system to assess the safety and efficacy of this therapy. The ELAD system incorporates cloned immortalized human liver cells (C3A cells). A hypothetical risk exists that, over an extended period of time, there may be an increased incidence of tumor in subjects treated with ELAD.

The company is also collecting data related to whether a patient received a liver transplant and on survival.

Eligibility criteria: Inclusion Criteria:

* Subjects participating in the VTI-206 clinical trial.

Exclusion Criteria:

* Subjects not participating in the VTI-206 clinical trial.

Primary outcomes:
measure: Gather data
timeFrame: Five years post study participation
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Vital Therapies, Inc.
name: Robert A Ashley
role: STUDY_DIRECTOR
References: